Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. Andy Hsieh of William Blair maintained a Buy rating on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) on March 12, expressing a positive outlook for the stock. His view is supported by the company’s advancing pipeline and improving regulatory clarity. Expected alignment with regulators on the pivotal trial designs for TN-201 and TN-401 could serve as a major de-risking event, offering clearer approval pathways and better visibility on potential value drivers and timelines.
Momentum into 2026 is backed by resumed enrollment in the MyPEAK-1 study for TN-201 and positive DSMB safety feedback on TN-401, allowing dose expansion. Early data from TN-301 is also important, as it expands the platform beyond gene therapy and could add a third growth pillar, supported by sufficient capital to execute current plans.
Tenaya Therapeutics, Inc. reported its fourth-quarter results on March 11, posting a GAAP EPS of -$0.12, which came in line with expectations. As of December 31, 2025, the company held $100.5 million in cash, cash equivalents, and investments in marketable securities, compared to $61.4 million at the end of December 2024. This increase reflects the additional net proceeds of $55.8 million raised through the December 2025 public offering, after accounting for underwriting discounts, commissions, and related expenses.
Tenaya Therapeutics, Inc. operates as a clinical-stage biotechnology company across the United States. It develops, discovers, and delivers therapies for heart disease. The company’s lead product candidates are TN-401, TN-201, and TN-301.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
